Immuron Ltd (IMRN) stock
IMRNNasdaqPharmaceutical PreparationsFiscal year ends June 30
$0.87−0.00 (-0.52%)
Close on Nov 18, 2026Market cap $6.99MP/E –Yield –
Immuron operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
For fiscal 2026 it was -A$3.85M. The highest annual figure on record is -A$2.87M in fiscal 2022.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Jun 30, 2026 | -A$3.85M | – |
| FY2025 | Jun 30, 2025 | -A$5.34M | – |
| FY2024 | Jun 30, 2024 | -A$5.80M | – |
| FY2023 | Jun 30, 2023 | -A$3.57M | – |
| FY2022 | Jun 30, 2022 | -A$2.87M | – |
| FY2021 | Jun 30, 2021 | -A$8.38M | – |
| FY2020 | Jun 30, 2020 | -A$2.91M | – |
| FY2019 | Jun 30, 2019 | -A$4.66M | – |
| FY2018 | Jun 30, 2018 | -A$3.05M | – |
| FY2017 | Jun 30, 2017 | -A$6.72M | – |
See a number that looks wrong?